

FACSIMILE TRANSMISSION

Transmission problems: (858) 720-2584

D c mber 20, 2001**OFFICIAL****FAX RECEIVED****DEC 21 2001****GROUP 1600****Brobeck**

ATTORNEYS AT LAW

Brobeck, Phleger & Harrison LLP
 12750 High Bluff
 Suite 300
 San Diego, California 92130-2081
 PHONE 858.720.2500
 FAX 858.720.3700
www.brobeck.com

PAGES TO FOLLOW COVER	5	USER ID	100454	CMID NUMBER	030639.0066.UTL1
-----------------------	---	---------	--------	-------------	------------------

TO

RECIPIENT	COMPANY	TELEPHONE	FAX
Assigned Examiner – TC 1614	U.S. Patent and Trademark Office	(703) 872-9306	

FROM

SENDER	EMAIL	TELEPHONE	FAX
Lisa McGeehan	lmcgeehan@brobeck.com	(858) 720-2584	(858) 720-3700

MESSAGE

Re: Application Serial No. 09/756,690

PRIVILEGED AND CONFIDENTIAL

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.

5DILIB1LM03420680.01

Received from <> at 12/20/01 12:34:37 PM [Eastern Standard Time]

17038729306

P.02/06

Patent

030639.0066.UTL1

13/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Young et al.

Serial No.: 09/756,690

Filed: January 9, 2001

Title: USE OF EXENDINS AND AGONIST
THEREOF FOR MODULATION OF
TRIGLYCERIDE LEVELS AND
TREATMENT OF DYSLIPIDEMIA

FAX RECEIVED

Group Art Unit: 1614

DEC 21 2001

Examiner: To Be Assigned

GROUP 1600

OPTIONAL

Commissioner for Patents
Washington, D.C. 20231PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the subject application, please enter the following amendment. Although it is believed that no fee is due for this submission, if any fee should become due or credit become payable during the pendency of these proceedings, the Examiner is authorized to charge or credit the same to deposit account number 50-1273.

AMENDMENTSIn the Specification

Please replace the paragraph bridging pages 11-12 with the following:

--Exendin agonist compounds include exendin acids, for example exendin-3 acid [SEQ ID NO. 185: His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser] and exendin-4 acid [SEQ ID NO. 186: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser]. Preferred exendin agonist compounds

CERTIFICATE OF TRANSMISSION
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being transmitted, via facsimile, to the United States Patent and Trademark Office on the date indicated below.

Lisa M. McGeehan
Lisa M. McGeehan

Date

12-20-01

C:\NrPortb\SDILIB1\1.M03420668_1.DOC